Proxima Clinical Research Experiences Fast Growth Following Brief Covid-19 DipView All articles
CRO doubles clients and triples clinical studies and staff over last nine months to bring hundreds of innovative healthcare products from concept to market, faster.
Houston, April 15, 2021― Proxima Clinical Research (“Proxima CRO”), a contract research organization (CRO) based out of the Texas Medical Center in Houston, announced today it has experienced tremendous growth in clients, regulatory projects, clinical studies, and new hires in the last half of CY 2020 and first quarter of CY 2021. In CY Q4 2020 alone, the company signed a new client every three days, onboarding 30 clients in 90 days. Today, Proxima CRO announced it has tripled its staff to service this extreme client growth and has plans to double again throughout 2021 and2022.
“We are excited about our rapid and continued growth,” says Kevin Coker, co-founder and CEO. “We designed Proxima to be the premiere clinical and regulatory resource to support the new class of rising stars in drugs, devices, diagnostics, and digital healthcare products. Emerging companies need flexibility, resources, guidance, and the ability to make decisions at speed, to a greater degree than established organizations. We pride ourselves on delivering the highest level of support and we are being rewarded for it in growth.”
The initial COVID-19 quarantine in Q1 and Q2 2020 not only negatively affected healthcare institutions, it paralyzed product innovation. The unchartered territory of a world-wide quarantine made it difficult for people to make decisions about future investments. However, by June, business was ready for its new normal, and Proxima CRO experienced an influx of clients ready to continue the surge of medical innovation.
“Although our regulatory, quality, and clinical advisory teams have worked on a number of EUA’s (Emergency Use Authorizations) and COVID related products, our recent growth has primarily been fueled by biotech and med tech products unrelated to COVID,” noted Coker.
Proxima CRO is specifically designed to be agile to assist new and aspiring inventors and emerging healthcare companies with clinical, regulatory, quality, and go-to-market strategies to get products approved and to market quickly. Services range from regulatory, quality, and clinical trial expertise to fundraising and guidance to bring products to market and launch emerging companies to success.
Proxima CRO has added 23 staff in the last nine months, six in the last four weeks, including Chelsea Isaac, Business Development Strategist; Elizabeth Abide, Marketing Strategist; and many others on the clinical and regulatory teams.
About Proxima Clinical Research
Proxima CRO provides the best regulatory and clinical research expertise to life sciences companies regardless of size or stage. With headquarters in the Texas Medical Center(TMC), the largest medical center in the world, Proxima CRO brings its expertise to hundreds of emerging medical device, pharmaceutical, biotechnology, and diagnostic companies in 17 countries across five continents to further advance the $130 billion market. Launched in November 2017, Proxima CRO is a registered Delaware C Corporation.
For more on Proxima CRO and its growing team, visit ProximaCRO.com.